The first 2016-issue of Current Pharmaceutical Biotechnology will be a review issue dedicated to latest research on acute myeloid leukaemia (AML). Prof. Frode Selheim at Department of Biomedicine and myself were guest editors, and we managed to get contributions from several outstanding researchers ranging from clinicians to natural compound chemists and microbiologists. I grouped with Dr. Gillian Barratt and Juliette Vergnaud, and PhD candidate Félix Sauvage, to write a review on the potential of using nanocarriers in AML therapy. You can find the whole list of papers here.